{"id":32313,"date":"2021-12-10T18:57:42","date_gmt":"2021-12-10T21:57:42","guid":{"rendered":"https:\/\/www.amarilfranklin.com.br\/?p=32313"},"modified":"2021-12-17T13:01:24","modified_gmt":"2021-12-17T16:01:24","slug":"resumo-de-noticias-semanal-03-12-a-10-12-2021","status":"publish","type":"post","link":"https:\/\/www.amarilfranklin.com.br\/index.php\/2021\/12\/10\/resumo-de-noticias-semanal-03-12-a-10-12-2021\/","title":{"rendered":"Resumo de Not\u00edcias Semanal \u2013 03\/12 a 10\/12\/2021"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.6.1″ _module_preset=”default” min_height=”100px” global_colors_info=”{}”][et_pb_fullwidth_image src=”https:\/\/www.amarilfranklin.com.br\/wp-content\/uploads\/Design-sem-nome-1.png” title_text=”Design sem nome (1)” admin_label=”Imagem de Largura Inteira” _builder_version=”4.6.1″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_fullwidth_image][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ transparent_background=”off” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Texto” _builder_version=”4.14.2″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” use_border_color=”off” border_color=”#ffffff” border_style=”solid” global_colors_info=”{}”]<\/p>\n

<\/h4>\n

\u200bO objetivo deste “Resumo Semanal de Not\u00edcias” \u00e9 reunir em pequenos t\u00f3picos o que aconteceu de mais relevante durante a \u00faltima semana.<\/span><\/h4>\n

Por Amaril Franklin Corretora<\/p>\n

10\/12\/2021<\/p>\n

Coronavirus<\/h2>\n\n\n\n\n
\n

1\u00aa Dose:<\/span><\/h4>\n
    \n
  • 164,9MM (77,1% da Popula\u00e7\u00e3o).<\/span><\/li>\n<\/ul>\n<\/td>\n

\n

2\u00aa Dose:<\/span><\/h4>\n
    \n
  • 138,9MM (65% da Popula\u00e7\u00e3o).<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n

\n

Dose de Refor\u00e7o:<\/span><\/h4>\n
    \n
  • 19,9 MM (9,3% da Popula\u00e7\u00e3o).<\/span><\/li>\n<\/ul>\n

    \u00a0<\/span><\/h4>\n<\/td>\n

\n

\u00a0<\/span><\/h4>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/h4>\n\n\n\n\n
\n

Total de casos:<\/span><\/h4>\n
    \n
  • 22,18MM (10,4% pop.)<\/span><\/li>\n<\/ul>\n<\/td>\n

\n

Recuperados:<\/span><\/h4>\n
    \n
  • 21,41MM (96,5% casos)<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n

\n

Em Tratamento:<\/span><\/h4>\n
    \n
  • 152,9 Mil (0,7% casos)<\/span><\/li>\n<\/ul>\n<\/td>\n

\n

Mortes:<\/span><\/h4>\n